Business
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence of neurodevelopmental benefit and suggest the potential for broader therapeutic impact CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targ
About this update from Camp4 Therapeutics Corporation
[{"type":"image","alt":"CAMP4 Therapeutics","displaySize":"","headline":null,"caption":"CAMP4 Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eH8rnGa.odLogUxnWG9sUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b","width":300,"height":94},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/eH8rnGa.odLogUxnWG9sUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b","width":300,"height":94}},"lazy":false},{"type":"text","content":"CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model","length":154,"tagName":"p"},{"type":"text","content":"Results build upon prior preclinical evidence of neurodevelopmental benefit and suggest the potential for broader therapeutic impact","length":132,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the presentation of new preclinical data for CMP-002, the Company's lead investigational antisense oligonucleotide (ASO) therapeutic candidate for SYNGAP1-related disorder (SRD), at the TIDES Oligonucleotide & Peptide Therapeutics conference on May 14, 2026.","length":666,"tagName":"p"},{"type":"text","content":"The new data demonstrate that CMP-002 administration produced a statistically significant improvement in both seizure threshold and severity of chemically-induced tonic-clonic seizures in mice haploinsufficient for SYNGAP1.","length":223,"tagName":"p"},{"type":"text","content":""SYNGAP1-related disorder is characterized by a constellation of neurological symptoms, of which seizures are among the most common, resulting in a devastating burden on patients and their families," said Daniel Tardiff...